Sports

Biotech stocks tumble on reports FDA's top vaccine regulator to leave

Peter Marks, who played a key role in U.S. President Donald Trump's first term in developing COVID-19 vaccines, will leave effective April 5, the Wall Street Journal and other media outlets reported on Friday. As director of the FDA's Center for Biologics Evaluation and Research, Marks has publicly supported programs that expedited the development of rare disease treatments and gene therapies during his tenure. Shares of gene therapy makers including Taysha Gene Therapies, Solid Biosciences and Sarepta Therapeutics were down between 4% and 10% in premarket trading.

Peter Marks, who played a key role in U.S. President Donald Trump's first term in developing COVID-19 vaccines, will leave effective April 5, the Wall Street Journal and other media outlets reported on Friday.

As director of the FDA's Center for Biologics Evaluation and Research, Marks has publicly supported programs that expedited the development of rare disease treatments and gene therapies during his tenure. Shares of gene therapy makers including Taysha Gene Therapies, Solid Biosciences and Sarepta Therapeutics were down between 4% and 10% in premarket trading..